Dahyot S, Lemee L, Pestel-Caron M
UNIROUEN, GRAM EA2656, laboratoire de bactériologie, CHU de Rouen, Normandie université, 76000 Rouen, France.
UNIROUEN, GRAM EA2656, laboratoire de bactériologie, CHU de Rouen, Normandie université, 76000 Rouen, France.
Rev Mal Respir. 2017 Dec;34(10):1098-1113. doi: 10.1016/j.rmr.2016.07.007. Epub 2017 Jul 5.
Acute pneumonias occur in a variety of clinical settings and accurate identification of bacterial causes is extremely important. No microbiological tool is either 100 % sensitive or 100 % specific, and despite investigations, aetiology remains unanswered in more than 30 % of pneumonia. No sample may be necessary for patients treated as outpatients, non invasive respiratory specimens are preferred in hospitalised individuals (community or healthcare associated), while invasive specimens are used as second line for community acquired pneumonia (CAP) in intensive care, and in the first line where pneumonia occurs in immunosuppressed patients. Bacterial cultures have an important place, if the sample is taken before the introduction of antibiotic therapy. Some contexts may justify the use of blood cultures, testing for urinary antigens or serology. PCR is already becoming available as a daily service but the short-term future probably belongs to molecular multiplex panels capable of detecting many microorganisms within hours, especially in severe CAP resuscitation and in pneumonia in the immunosuppressed. High-throughput sequencing nucleotide techniques will soon revolutionize microbiological diagnosis in respiratory medicine, as in other areas of infectious diseases.
急性肺炎发生于多种临床环境中,准确识别细菌病因极为重要。没有任何微生物学检测工具能达到100%的敏感性或100%的特异性,尽管进行了各种检查,但仍有超过30%的肺炎病例病因不明。门诊治疗的患者可能无需采样,住院患者(社区获得性或医疗保健相关性)首选非侵入性呼吸道标本,而侵入性标本在重症监护中作为社区获得性肺炎(CAP)的二线检测手段,在免疫抑制患者发生肺炎时则作为一线检测手段。如果在使用抗生素治疗前采集样本,细菌培养具有重要地位。在某些情况下,血培养、尿抗原检测或血清学检测可能是合理的。聚合酶链反应(PCR)已经成为日常检测手段,但在不久的将来,可能是能够在数小时内检测多种微生物的分子多重检测板占据主导地位,尤其是在重症CAP复苏和免疫抑制患者的肺炎检测中。高通量测序核苷酸技术很快将彻底改变呼吸医学以及其他传染病领域的微生物学诊断。